Paradigm Health has raised $78 million in an oversubscribed Series B financing round led by ARCH Venture Partners, marking one of the company’s most significant capital infusions as it accelerates efforts to make clinical trials part of routine care across the United States and globally. The round included participation from new investor DFJ Growth, along with existing backers F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, and the American Cancer Society’s BrightEdge Fund, several of which increased their commitments through super pro rata positions.
The company, which focuses on rebuilding the clinical research ecosystem, plans to use the new capital to expand nationally and internationally as demand surges from global biopharmaceutical companies seeking more efficient trials and from health systems aiming to offer trial options directly within routine care settings. Paradigm Health currently supports Phase I through Phase III oncology trials for 15 of the world’s 20 largest pharmaceutical companies, reflecting the breadth of its adoption.
Following Paradigm Health’s acquisition of Flatiron Health’s Clinical Research Business, the company now operates the country’s largest oncology research network and is extending its commercial footprint into neuroscience, cardiovascular disease, metabolic conditions, and other areas with substantial research needs. The company continues scaling its infrastructure to help community and rural health systems participate in research without the extensive staffing and administrative burdens that traditionally limit trial access for these patient populations.
Paradigm Health’s platform spans 45 states and 166 healthcare provider organizations, reaching 2,100 care locations and placing an estimated 70% of the U.S. cancer population within reach of a clinical trial site. The company’s AI-enabled technology automates patient matching, site feasibility analysis, and administrative processes, enabling health systems to accelerate patient accrual by 4x while reducing provider burden and helping biopharma sponsors move promising therapies through development more quickly. The company has also introduced a Trial Design Service that allows sponsors to design and execute interventional and pragmatic trials embedded directly into real-world clinical workflows.
The company sees a sizeable opportunity as artificial intelligence drives rapid drug discovery and creates demand for research infrastructure capable of handling dramatically higher trial throughput. With a national network, a technology-driven platform, and new services focused on embedded trial design, Paradigm Health aims to serve as the leading partner for biopharmaceutical companies and health systems seeking to seamlessly integrate clinical research into patient care.
KEY QUOTES:
“When trials run more efficiently, new treatments reach patients sooner. Paradigm Health is creating new infrastructure the industry desperately needs: one platform that enables hospitals and sponsors to run studies faster, more intelligently, and at far lower cost. This will accelerate the development of promising therapies and help ensure today’s patients have access to the treatments they need.”
Robert Nelsen, Managing Partner at ARCH Venture Partners and Paradigm Health Co-Founder and Board Chair
“Clinical trials are how we learn and improve care for patients. Today, most research happens in academic centers because they have the staff and infrastructure to manage it. Patients in community and rural settings have limited access to trials, and their experiences remain underrepresented in research. This slows down trials, makes them more expensive, and misses opportunities for innovation. Paradigm Health is building a scalable trial ecosystem embedded directly into real-world clinical workflows, enabling any health system to participate in research with dramatically fewer resources.”
Kent Thoelke, Chief Executive Officer of Paradigm Health
“Clinical trials are the bottleneck in getting new therapies to patients, especially as AI unlocks an unprecedented wave of drug innovation. Paradigm Health is the AI-native platform built for this moment, pairing breakthrough technology with the largest clinical network to make trials dramatically faster and more accessible. We’re excited to support the team as they democratize access to cutting edge therapies.”
Justin Kao, Partner at DFJ Growth
